Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
about
Resistant mechanisms to BRAF inhibitors in melanomaThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibState of the science on prevention and screening to reduce melanoma incidence and mortality: The time is nowThe steady progress of targeted therapies, promising advances for lung cancerUpdate on rational targeted therapy in AMLCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyUpdates in Therapy for Advanced MelanomaMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaNew therapeutic strategies for BRAF mutant colorectal cancersOral targeted therapy for cancerMedical management of malignant melanomaMelanoma: oncogenic drivers and the immune systemTailoring the Treatment of Melanoma: Implications for Personalized MedicinePembrolizumab: First in Class for Treatment of Metastatic MelanomaRecent advances in the treatment of melanoma with BRAF and MEK inhibitorsBRAF Mutation in Colorectal Cancer: An UpdateTrametinib: a MEK inhibitor for management of metastatic melanomaManaging Side Effects of Vemurafenib Therapy for Advanced MelanomaMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetMelanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterPilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistancePrimary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeBeyond RAS and BRAF: a target rich disease that is ripe for pickingThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerRecent advances in the biology of human circulating tumour cells and metastasisBRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapyCombination therapeutics in complex diseasesSystemic Therapies for Late-stage MelanomaAlternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem CellsCrucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsUse of a Tissue Engineered Human Skin Model to Investigate the Effects of Wounding and of an Anti-Inflammatory on Melanoma Cell InvasionCombined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNivolumab and ipilimumab versus ipilimumab in untreated melanomaSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
P2860
Q26739717-14B77AE6-FE3C-4BBC-88A3-BAFBE6ADED62Q26744335-813A3EC2-3320-4052-8F71-4D1457E4BA6AQ26745557-B3456913-06FE-40F6-9003-E7BEC02B31D9Q26746895-4731EDD9-2EEC-4678-AD8B-44AE38721722Q26766152-8E79F320-D0F1-4CEC-BFD4-44226D2B5A25Q26769870-B2C40C9E-2040-48DE-8016-B6273FCE14D8Q26771119-AE3BD22F-1F2C-4313-BFD5-601B478708E3Q26771192-F9B25A48-C310-414E-B8B8-DA8FD49A0C41Q26772015-6D790D80-6391-4871-AAAD-801CB4F7765AQ26772277-BAC91BC5-5559-4C33-8E62-220B1D464564Q26773240-B3CE9B89-D308-4110-B1E1-1EF4C28E1B04Q26773302-32C95443-7938-4504-9A42-94E95282CECEQ26775598-26C96097-32C4-4C9E-B529-023513B05D50Q26775806-BF764C0B-43B3-4FCB-A741-55D638A41F5CQ26777886-3513E41E-DDA0-4B9B-A61B-8FF15458F3B7Q26778769-213C7405-42FE-4180-9E0C-808C0BD3FCB5Q26781926-B4EC5133-471B-4BA8-B981-8F0FCAD97DA4Q26782976-F75FB219-9954-40A9-82D7-8B04DA23742DQ26795510-E4D00E2D-B606-4931-ADFE-935EBB6BD98BQ26795735-06BFD5A0-E325-4F29-89D5-25533AFC732DQ26799864-04769590-B9DC-4356-8A82-B41AA0D991CFQ27314686-00805284-6952-4786-A5DD-D0B84765270EQ27853121-98396545-52C3-4AA5-969F-BF3BAEF3B7EEQ27853210-0ABB28A5-6FA1-4CDB-9667-FC0BC66726E9Q27853295-4C7DC1ED-6432-4466-B10D-D3721671B9E7Q28066095-40041419-D4C9-453D-81BA-5C3A830E74E6Q28067196-F6252CAA-846B-4675-9ABF-B6011C59DA8AQ28070120-481C1255-1B04-4995-AE51-1E793A6D673CQ28076667-40BEE8B7-6782-45AD-A1E7-05AA82BA5E10Q28076891-B27D486E-ED75-4950-9AE4-2713F272EB0DQ28080215-00EF542C-F110-45D4-A443-7BF487CEEB76Q28084243-06736C88-8F76-4CFB-A8F0-9F5A2D10768BQ28115187-97D66BF6-7DB9-4B3B-A6A5-117438548CE9Q28468571-231AC0F2-23AC-4534-B278-44D1F949CD2BQ28550092-EC09B031-13B1-4CED-A0DE-C35C26325261Q29615443-92D9CB09-A767-4EF5-9725-ADE7FCD50556Q29620657-085E0322-AEA4-4B5E-BD44-171AF99EE5A1Q30239901-389F99E9-5A3F-45AF-9CAF-D4754FBADE3BQ30277902-DEEEDC59-5024-4CD2-9072-9BF5B50E68AAQ30400081-DCD272C9-3B89-45E0-9558-55C9EE2626B5
P2860
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@ast
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@en
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@nl
type
label
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@ast
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@en
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@nl
prefLabel
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@ast
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@en
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@nl
P2093
P50
P356
P1476
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
@en
P2093
Anne-Marie Martin
Antoni Ribas
Axel Hauschild
Celeste Lebbe
Claus Garbe
Daniele Ouellet
Douglas J DeMarini
Helen Gogas
James Larkin
Jean Jacques Grob
P304
P356
10.1056/NEJMOA1406037
P407
P50
P577
2014-09-29T00:00:00Z